Overview
Pharma Engine
?
Management, Scientific, and Technical Consulting Services
,
Pharmaceutical and Medicine Manufacturing
,
Scientific Research and Development Services
,
Industry specialist consultants
,
Drugs and herbs: grading, grinding, and milling
See All Industries Medical research, commercial
See Fewer Industries
See All Industries Medical research, commercial
See Fewer Industries
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Other Professional, Scientific, and Technical Services
,
Scientific Research and Development Services
,
Specialized Design Services
?
?
?
Actual
?
Actual
$77.68 million
Actual
228.7%
537.55%
$5,847
DEC
?
?
GreTai:4162
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$77.68 million
USD
Actual
1 USD = 32.4834 TWD
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $14 | $8 | $6 |
| Net Investing Cash | -$4 | -$26 | -$6 |
| Net Financing Cash | -$7 | -$9 | -$12 |
| Net Change in Cash | $4 | -$27 | -$12 |
| Cash at Beginning of Period | $27 | $54 | $66 |
| Cash at End of Period | $31 | $27 | $54 |
| Capital Expenditure | -$0 | -$0 | -$0 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $31 | $27 | $54 |
| Accounts Receivable | $2 | $2 | $2 |
| Inventories | $1 | $0 | $1 |
| Other Current Assets | $146 | $91 | $63 |
| Asset Summary | |||
| Total Current Assets | $179 | $121 | $121 |
| Tangible Fixed Assets | $0 | $1 | $1 |
| Intangible Assets | $ | $ | $ |
| Total Assets | $5,848 | $3,954 | $3,967 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $ | $ | $ |
| Short-Term Debt | $ | $ | $ |
| Other Current Liabilities | $14 | $3 | $2 |
| Liability Summary | |||
| Total Current Liabilities | $14 | $3 | $2 |
| Long-Term Debt | $ | $ | $ |
| Other Long-Term Liabilities | $ | $ | $ |
| Total Liabilities | $14 | $3 | $3 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $45 | $45 | $45 |
| Retained Earnings | $66 | $19 | $20 |
| Equity Summary | |||
| Total Equity | $166 | $119 | $119 |
| Shares Outstanding | 143,677,940 | 143,677,000 | 143,686,000 |